Extended Data Fig. 8: In vivo correlation of antibody-mediated protection against SARS-CoV-2.
From: In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
For each panel, the fold change in the EC50 values of the indicated mAb or mAb cocktails between the N501Y/D614G strain and one or more variants of concern (B.1.1.7, Wash-B.1.351 or Wash-B.1.1.28) were plotted on the x axis. Next, the fold change in lung viral RNA titre corresponding to the indicated treatment group (top labels) between the N501Y/D614G strain and one or more variants of concern (B.1.1.7, Wash-B.1.351 or Wash-B.1.1.28) were plotted on the y axis. Best-fit lines were calculated using a simple linear regression. Two-tailed Pearson correlation was used to calculate R2 and P values indicated within each panel.
